Elicio Therapeutics closes $20M convertible note private placement at $5.81 conversion price

Elicio Therapeutics, Inc.

Raised $20M via 3% senior secured convertible note due Feb 2026; net proceeds ~$19.7M.
Conversion price $5.81 per share (~135% of Aug 9 close); subject to stockholder approval.
Purchaser GKCC LLC is controlled by a board member (related-party transaction).
Proceeds to be used for working capital and general corporate purposes.
Note is secured by first-priority lien on substantially all assets and intellectual property.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.